PNC Financial Services Group
CLDI.WS

PNC Financial Services Group’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

PNC Financial Services Group’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50
Closed -$3 – 4943
2024
Q1 		$3 Hold
50
– – ﹤0.01% 4686
2023
Q4 		$2 Hold
50
– – ﹤0.01% 4613
2023
Q3 		$11 Buy
+50
New +$9 ﹤0.01% 4596

Other funds holding CLDI.WS

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

PNC Financial Services Group's CLDI.WS Position: Q2 2024 in Review

PNC Financial Services Group sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q2 2024, closing a stake of 50 shares — an estimated $3 sold.

PNC Financial Services Group first reported a position in CLDI.WS in Q3 2023 and held it in 3 quarters. The position peaked at $11 in Q3 2023. 15 funds tracked by Wall St. Rank hold CLDI.WS as of Q2 2024.

  • PNC Financial Services Group reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q2 2024 after selling out during the quarter.
  • PNC Financial Services Group sold 50 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q2 2024, an estimated $3.
  • PNC Financial Services Group first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q3 2023 and held it in 3 quarters.
  • PNC Financial Services Group's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $11 in Q3 2023.
  • 15 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q2 2024.

Based on PNC Financial Services Group's 13F filing for Q2 2024, filed 9 Aug 2024.